Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03071172
Other study ID # GenSci 067 CT
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received February 20, 2017
Last updated February 28, 2017
Start date March 2017
Est. completion date May 2018

Study information

Verified date February 2017
Source GeneScience Pharmaceuticals Co., Ltd.
Contact Rui Yang
Phone 010-82265080
Email yrjeff@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study was to evaluate the efficacy and safety of domestic recombinant human follicle stimulating hormone (rhFSH) stimulating ovarian to promote follicular development before assisted reproductive technology, which was non-inferiority than that of the imported rhFSH.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 252
Est. completion date May 2018
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 39 Years
Eligibility Inclusion Criteria:

- Age is more than 20 years old and less than 39 years old, married.

- Applicable for ART controlled ovarian hyperstimulation, such as IVF/ET, ICSI, GIFT, ZIFT and so on.

- Regular menstrual cycle (25-35 days).

- 18kg/m2=BMI<30kg/m2.

- The level of basic serum FSH <10IU / L in the 2nd-5th days of the menstrual cycle, the luteinizing hormone, estradiol and progesterone levels were normal.

- The screening period or recent three months of vaginal ultrasound examination showed that the shape of bilateral ovarian and uterine size were normal and 5 = number of basal antral follicle in unilateral ovarian <10, and follicular diameter <10 mm.

- The in vitro fertilization and embryo transfer (IVF/ET) and (or) intracytoplasmic sperm injection (ICSI) technology were less than three times used prior to the reproductive treatment (provide copies of previous cases).

- Volunteer to participate and sign informed consent.

Exclusion Criteria:

- There are high risk of ovarian hyperstimulation syndrome (OHSS), such as the subject who has high response to gonadotropin in the previous ovarian hyperstimulation cycle, polycystic ovary syndrome (PCOS), the subject who has severe OHSS cancellation cycle.

- Affect the outcome of pregnancy-related diseases (any one): untreated hydrosalpinx, untreated uterine polyps, untreated uterine infection, stage ? ~ IV endometriosis, ovarian cyst> 4cm , uterine fibroids diameter> 4cm, pelvic benign tumor> 4cm, pituitary tumors and malignant tumors of tissues and organs.

- The subject has abnormal uterine bleeding.

- Affect pregnancy-related endocrine and metabolic diseases (any one): hyperprolactinemia, thyroid disease (including hyperthyroidism, hypothyroidism), hyperandrogenism, adrenal dysfunction (including adrenal hyperfunction, adrenal cortical dysfunction).

- The subject has severe liver and kidney dysfunction, which the levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are 2.5 times higher than the upper limit of normal value, and serum creatinine (Cr) and urea nitrogen (BUN) are 2 times higher than the upper limit of normal value.

- Severe heart disease, unstable angina pectoris, heart failure grade ? above, acute myocardial infarction and/or old myocardial infarction, hypertension diagnosed according to the 2010 edition of the Chinese Hypertension Prevention Guidelines.

- The subject who have contraindications or allergic history for gonadotropin-releasing hormone agonists (GnRH-a), rFSH/human menopausal gonadotropin (hMG), human chorionic gonadotropin (hCG), progesterone drugs.

- Positive HIV or syphilis.

- The subject has alcoholism, smoking, drug abuse, bad drug abuse habits.

- At least one of the spouses has received sperm donor or egg donor or PGD (genetic diagnosis before embryo transfer) and PGS (Preimplantation of embryos before genetic screening)?

- The subject received clomiphene or gonadotropin therapy within 1 month before screening?

- The subject was participated in last three months or are participating in other clinical research?

- Patients with positive serum pregnancy test.

- The investigators considered the subject inappropriate to be enrolled in this study.

Study Design


Related Conditions & MeSH terms

  • Ovarian Hyperstimulation Syndrome

Intervention

Drug:
Triptorelin for Injection
Drugs for IVF-ET (in vitro fertilization and embryo transfer).
Recombinant Human Choriogonadotropin alfa Solution for Injection
Drugs for IVF-ET (in vitro fertilization and embryo transfer).
Progesterone Soft Capsules
Drugs for IVF-ET (in vitro fertilization and embryo transfer).

Locations

Country Name City State
China Peking University Third Hospital Beijing
China Xiangya Hospital Central South University Changsha Hunan
China Sun Yat-sen Memorial Hospital Guangzhou Guangdong
China The Sixth Affiliated Hospital of Sun Yat-sen University Guangzhou Guangdong
China Women's Hospital School of Medicine Zhejiang University Hangzhou Zhejiang
China The first Affiliated Hospital of Anhui Medical University Hefei Anhui
China Jiangsu Province Hospital Nanjing

Sponsors (8)

Lead Sponsor Collaborator
GeneScience Pharmaceuticals Co., Ltd. Peking University Third Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital with Nanjing Medical University, Women's Hospital School Of Medicine Zhejiang University, Xiangya Hospital of Central South University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The total number of oocytes obtained during the start-up period Routine ova harvest to determine the number of obtained oocytes On the days of ovum picking up (hCG trigger 36-38h)
Secondary The number of follicle-1 The number of follicle with diameter more than 18mm on the day of hCG day
Secondary The number of follicle-2 The number of follicle with diameter more than 18mm on the fifth day of rhFSH ovarian stimulation
Secondary Number of 2PN oocytes Collected on the day of embryo transfer day after three days of ovum picking up.
Secondary Number of metaphase II oocytes Collected on the day of embryo transfer day after three days of ovum picking up, which only collected during ICSI cycle.
Secondary Number of transferred embryos Collected on the day of embryo transfer day after three days of ovum picking up.
Secondary Number of high quality embryos Collected on the day of embryo transfer day after three days of ovum picking up.
Secondary Fresh cycle embryo implantation Collected on the day of embryo transfer day after three days of ovum picking up.
Secondary rhFSH administered days and vials; administered total dose of rhFSH (IU) Collected on the day of hCG day.
Secondary Serum E2 level Collected on the day of hCG day.
Secondary High quality embryos rate Collected on the day of embryo transfer day after three days of ovum picking up.
Secondary Fertilization rate Collected on the day of embryo transfer day after three days of ovum picking up.
Secondary Fresh cycle embryo implantation rate Collected between 28-35 days after embryo transfer.
Secondary Biochemical pregnancy rate Collected between 14-16 days after embryo transfer.
Secondary Clinical pregnancy rate Collected between 28-35 days after embryo transfer.
Secondary Continuous pregnancy rate Collected after 12 weeks of embryo transfer.
Secondary The number of follicle-3 The number of follicle with diameter between 14mm and 18mm. on the day of hCG day
Secondary The number of follicle-4 The number of follicle with diameter less than 14mm on the day of hCG day
Secondary Endometrium thickness (mm) on the day of hCG
See also
  Status Clinical Trial Phase
Withdrawn NCT00617864 - The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome N/A
Withdrawn NCT01979341 - The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes N/A
Completed NCT01427335 - Calcium for Prevention of Ovarian Hyperstimulation Syndrome Phase 3
Completed NCT01014104 - Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome Phase 1/Phase 2
Recruiting NCT00119925 - 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists" N/A
Terminated NCT01714648 - Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome? Phase 4
Completed NCT01500863 - Endometrial Receptivity After GnRH Agonist Triggering Phase 4
Recruiting NCT00417144 - Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Phase 4
Completed NCT03876145 - The Four Methods of Ovarian Stimulation in Patients With Polycystic Ovarian Syndrome N/A
Completed NCT05588635 - Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy
Not yet recruiting NCT02392520 - Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS) N/A
Completed NCT00665041 - Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome Phase 2
Completed NCT00835523 - Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist N/A
Active, not recruiting NCT05638529 - Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome Phase 4
Recruiting NCT02084940 - Long Acting GnRH Antagonist in PCOS Women Undergoing IVF N/A
Completed NCT01815138 - Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS Phase 4
Completed NCT00867659 - The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors N/A
Completed NCT01569256 - Ovarian Hyperstimulation Syndrome and Cabergoline N/A
Not yet recruiting NCT05198128 - Ovarian Hyperstimulation Syndrome Using Calcium Infusion N/A
Completed NCT02200952 - Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSS